CPX-351治疗高危骨髓增生异常综合征和慢性粒单核细胞白血病:一项多中心、单臂、2期研究
这项由法国骨髓增生异常综合征工作组开展的2期单臂研究纳入31例初治高危MDS或CMML患者,给予CPX-351诱导治疗,总缓解率为87%(27/31,95%CI 70-96),94%的患者接受异基因造血干细胞移植,最常见3-4级不良事件为肺部(26%)和心血管(19%),无治疗相关死亡。
要点
- CPX-351诱导后总缓解率为87%(27/31,95%CI 70-96)。
- 94%(29/31)的患者接受了异基因造血干细胞移植。
- 最常见3-4级不良事件为肺部(8/31,26%)和心血管(6/31,19%),无治疗相关死亡。
核心结论
- CPX-351在高危骨髓增生异常综合征和慢性粒单核细胞白血病患者中似乎有活性且安全,使大多数患者得以桥接至异基因造血干细胞移植。
研究设计与样本
- 研究者发起的2期试验,由法国骨髓增生异常综合征工作组开展,法国12个中心参与,包括队列A(本文报告,已完成)和队列B(因入组不足而停止,本文未报告)。
- 队列A纳入年龄18-70岁、ECOG体能状态0-1的新诊断高危骨髓增生异常综合征或慢性粒单核细胞白血病患者,共31例。
- CPX-351(含阿糖胞苷100 mg/m2和柔红霉素44 mg/m2)静脉给药,第1、3、5天;若未达至少部分缓解,给予第二个诱导周期(相同日剂量,第1、3天);缓解者可接受最多4个月期巩固周期(相同日剂量,第1天)或异基因造血干细胞移植。
主要发现
- 2020年4月29日至2021年2月10日入组21例(68%)男性和10例(32%)女性患者。
- 31例患者中27例(87%)缓解(95%CI 70-96)。
- 31例患者中16例(52%)接受至少一个巩固周期。
- 31例患者中30例(97%)初始被认为适合异基因造血干细胞移植,29例(94%)接受了该操作。
- 中位随访16.1个月(IQR 8.3-18.1);最常见3-4级不良事件为肺部(8/31,26%)和心血管(6/31,19%);共14例严重不良事件(主要为感染住院[n=5],仅1例与治疗相关),无治疗相关死亡。
关键数值与推荐
- 主要终点为根据欧洲白血病网2017急性髓系白血病标准,在CPX-351诱导后(无论接受一个还是两个诱导周期)一或两个诱导疗程后的总缓解率。
- 安全性在所有入组患者(队列A)中评估。
临床怎么用
- CPX-351似乎在高危骨髓增生异常综合征和慢性粒单核细胞白血病患者中有活性且安全,使大多数患者得以桥接至异基因造血干细胞移植。
局限性
- 队列B因入组不足(即足够患者不符合入组标准)而停止,本文未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: CPX-351, an encapsulated form of cytarabine and daunorubicin, has shown greater efficacy than the classic 3 + 7 treatment administration in secondary acute myeloid leukaemia. Given that higher-risk myelodysplastic syndrome and chronic myelomonocytic leukaemia share similarities with secondary acute myeloid leukaemia, we aimed to investigate the safety and efficacy of CPX-351 in this context. METHODS: This investigator-initiated two-cohort phase 2 trial was conducted by the Groupe Francophone des Myélodysplasies, with 12 participating centres in France. It comprised cohort A (reported here and completed), which included patients in first-line treatment, and cohort B, which was stopped for lack of inclusion (ie, not enough patients met the inclusion criteria), for patients with hypomethylating agent failure that is not reported here. Cohort A enrolled patients with newly diagnosed higher-risk myelodysplastic syndrome or chronic myelomonocytic leukaemia (aged 18-70 years old) with an Eastern Cooperative Oncology Group performance status of 0-1. Intravenous CPX-351 (100 mg/m2 cytarabine and 44 mg/m2 daunorubicin) was given on days 1, 3, and 5, with a second induction cycle given (same daily dose on days 1 and 3) if at least a partial response was not reached. Patients who responded could receive up to four monthly consolidation cycles (same daily dose on day 1) or allogeneic haematopoietic stem-cell transplantation (HSCT). Overall response rate after one or two induction courses according to European LeukemiaNet 2017 acute myeloid leukaemia was the primary endpoint after CPX-351 induction, whether patients received one or two induction cycles. Safety was assessed in all patients enrolled (in cohort A). This trial is registered with ClinicalTrials.gov, NCT04273802. FINDINGS: Between April 29, 2020, and Feb 10, 2021, 21 (68%) male and ten (32%) female patients were enrolled. 27 (87%) of 31 patients responded (95% CI 70-96). 16 (52%) of the 31 patients received at least one consolidation cycle. 30 (97%) of the 31 patients included were initially considered eligible for allogeneic HSCT and 29 (94%) of the 31 patients had the procedure. Median follow-up was 16·1 months (IQR 8·3-18·1). The most common grade 3-4 adverse events were pulmonary (eight [26%] of 31 patients) and cardiovascular (six [19%] of 31 patients). There were 14 serious adverse events (mainly hospitalisation for infection [n=5] and only one was treatment-related) and no treatment-related death. INTERPRETATION: CPX-351 appears to be active and safe in patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukaemia, allowing bridging to allogenic HSCT in most patients. FUNDING: Jazz Pharmaceuticals.
引用
- Peterlin P, Le Bris Y, Turlure P, et al. CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Haematol. 2023. PMID: 37245522. doi:10.1016/S2352-3026(23)00090-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。